arrow
A

Alessandro Lucchesi

irccs istituto romagnolo per lo studio dei tumori (irst) 'dino amadori'
H指数:21
被引数:1,566

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy

成人原发免疫性血小板减少症患者皮下注射治疗的实际经验:一项对意大利患者和临床医生的双横断面调查研究

2026-08-260
PRE
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)

意大利前瞻性研究(ROMEI)中,IPSS中危-1风险骨髓纤维化患者接受鲁索利替尼治疗的临床结果:中期分析

2026-03-250
OAAI
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study

PNH克隆在Ph阴性骨髓增殖性肿瘤中的流行病学研究:一项意大利多中心研究

2025-08-220
OAAI
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机III期试验

2025-03-102
OA
Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

伊美特尔stat 与最佳可用疗法在 IMpactMF 随机、开放标签、III 期试验中对接受过或难治于 Janus 激酶抑制剂的中间-2 或高风险骨髓纤维化患者中的比较

BLOOD
IF23.1
2024-11-053
PRE
ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

ASXLI突变在诊断时并未影响慢性期(CP)慢性粒细胞白血病(CML)患者(pts)在SUSTRENIM临床试验中接受尼洛替尼(NIL)一线治疗或伊马替尼(IM)联合早期切换至尼洛替尼(NIL)(在无最佳应答情况下)的分子应答深度(MR)及无治疗缓解(TFR)资格。

BLOOD
IF23.1
2024-11-051
PRE
Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naive Patients with Myelofibrosis

佩拉布雷昔布与鲁索利替尼联合治疗Janus激酶抑制剂初治骨髓纤维化患者的III期Manifest-2研究最新结果

BLOOD
IF23.1
2024-11-052
PRE
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

细胞因子调节与接受Nuvisertib(TP-3654)治疗骨髓纤维化患者的症状改善显著相关,Nuvisertib是一种在研的选择性PIM1激酶抑制剂。

BLOOD
IF23.1
2024-11-050
PRE
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
2024-07-021
OAAI
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
2021-10-188
OAAI
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
2021-08-1822
OAAI